Prof Jagat Kanwar

STAFF PROFILE

Position

Professor In Nanomedicine

Faculty

Faculty of Health

Department

School of Medicine

Campus

Geelong Waurn Ponds Campus

Qualifications

Bachelor of Science, , 1984
Master of Science, Punjabi University, 1988
Doctor of Philosophy, Postgrad Inst of Med Edu & Res, 1993

Biography

Degree/Award Year Discipline/Field Organisation and Country

  1. PhD 1993: Biotechnology (Medical Biochemistry & Immunology): Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
  2. MSc 1988: Medical Biochemistry: College of Basic Sciences, PAU, Ludhiana, Punjab, India
  3. BSc 1984: Medical Sciences: Himachal Pradesh University, Shimla, Himachal Pradesh, India

Current and previous appointment

  • BEd-Sc (Bachelor of Education Science) 1985: Guru Nanak Dev University, Amritsar, Punjab, India
  • Research Fellow The University of Auckland, NZ Department of Molecular Medicine & Pathology Jan 1997-Dec 2001
  • Senior Scientist/Senior Research Fellow The University of Auckland, NZ Department of Molecular Medicine & Pathology Jan 2001-March 2006
  • Associate Professor of Immunology & Cell Biology, Team Leader of Nanomedicine Laboratory (NLIMBR) Deakin University, Australia Centre for Biotechnology and Interdisciplinary Sciences (BioDeakin), March 2006-2013
  • Professor of Nanomedicine, Team Leader of Nanomedicine Laboratory of Immunology & Molecular Biomedical Research (NLIMBR) Deakin University, Australia School of Medicine, Faculty of Health 2013- to date

 

Professor Jagat Kanwar has received his PhD in 1992 from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University, Australia, in 2006, he was Senior Scientist in the University of Auckland, New Zealand. We seek to explore the roles of molecular mediators, antioxidants and cellular communication in the pathophysiological mechanisms of chronic inflammatory, microbial diseases and cancer. Our research combines immunology with state of the art and cutting edge techniques in molecular biology, biochemistry, nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed. Our objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. We carry out both academic and commercial research projects and develop new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems for the prevention of human diseases like cancer, vision abnormalities, infectious, inflammatory bowel disease (IBD), neurodegenerative, osteoarthritis, cardiovascular and pulmonary diseases. NLIMBR through national and international collaborations aims in near future to translate discoveries into new approaches for the diagnosis, treatment, and prevention of human diseases.

Our recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with anti-tumour proteins, peptides, siRNA, shRNA, miRNA, LNA modified nucleic acids, and/or drug molecules which specifically target cells. We are developing nano-medicinal based war against cancer/inflammatory cells with double targeted nano-bullet nanocapsules that specifically induce their traumatic death in cancer cells, chronic inflammatory cells and transformed cloudy myofibroblast cells, and spare normal body cells. The success behind our team is, working as a unit in creating and maintaining a healthy and work friendly environment.

Read more on Jagat's profile

Biography summary

Professor Kanwar is the group leader and laboratory head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research in School of Medicine, Faculty of Health at Deakin University. His earlier research (for nearly a decade in New Zealand) has focused on studying pathophysiology and devising new treatments mainly for cancer and chronic inflammatory diseases. Prof. Kanwar is currently working on nanotechnology/nanomedicine based protein/peptide, aptamers and his research approach employs monotherapy (gene therapy, immunotherapy) and combinational therapy with commercially available chemotherapeutic agents including LNA-aptamers (RNA/DNA), peptides and other biomolecules such as siRNA, miRNA, aptamers, proteins, siRNA, miRNA and their chimera (LNA-aptamer chimera with siRNA/miRNA delivery for targeting expression of survivin (the validated anti-cancer target), HIF-1 and apoptotic signalling molecules’ in cancer and chronic inflammation.

 

We are discovering novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in regeneration, apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of osteoarthritis, atherosclerosis, myocardial infarction, ocular inflammations, corneal haze, age related macular degeneration, glaucoma and ocular drug delivery. Apart from these we also work on microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes.

Career highlights

March 2006 - ongoing: Associate Professor of Immunology & Cell Biology, Institute of Technology Research and Innovation, Deakin University, Australia
Jan 2002: Senior Scientist/Senior Research Fellow, The University of Auckland, Auckland, NZ
Jan 1997: Research Fellow, The University of Auckland, Auckland, NZ

Research interests

Professor Jagat Kanwar is the group leader and laboratory head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR) in School of Medicine, Faculty of Health at Deakin University. He has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He is an immunologist, molecular biologist and cell biologist. He has extensive training and expertise in studying the molecular mechanisms and in devising treatments for human diseases like cancer (colon, breast, liver, prostate and retinoblastoma) and chronic inflammatory diseases such as asthma, atherosclerosis, inflammatory bowel disease (IBD), arthritis, multiple sclerosis including corneal haze, age related macular degeneration (AMD) in both in vivo and in vitro models.

Current Research Aims:
An immense focus of the group is to develop non-conventional therapeutics involving compounds for cancer and other inflammatory diseases. Nanomedicine is the need for the day to develop, synthesise and characterize of nanoformulations that can achieve a more targeted and specific delivery system is being carried out in the NLIMBR laboratory. Extensive research is carried out for development and physio-chemical characterization of biodegradable and biocompatible drug delivery vehicles. Novel targeted delivery systems possessing enhanced permeation retention effect, stability and narrow size range have been successfully synthesised. A number of other developments including microfluidics, nanodevices, nanosensers and microchips for targeted delivery and diagnosis are also our major interests. The principle aim is to achieve a system where there is a diagnostic and therapeutic approach to target cancer and other inflammatory conditions. Recently microfluidic systems being worked upon are targeting an approach to less time consuming and more economic methods for cancer and microbial infection diagnosis.

Teaching interests

Interests in innovations in medical biotechnology, nanotechnology and nanomedicine teachings

Units taught

  • 2005-2016: HMM302 - Innovations in Medical Biotechnology in Faculty of Health.
  • 2006-2012: SEK320 Nanobiotechnology -IFM-1-2012
  • 2008-2012: SEK302 Nanomedicine (Unit Chair Semester 2)
  • 2006-2011: SBB323 Immunology (Unit Chair Semester 2)

Knowledge areas

CANCERS: Development of locked nucleic acid (LNA) modified aptamers/siRNA nanocapsules based multimodular therapy to target cancer drug resistance stem cells and monitor tumours by real-time live imaging. Survivin inhibition has come across as a powerful approach for inducing drug sensitivity and inhibiting metastasis. Our group has shown that survivin inhibition using more stable locked nucleic acid (LNA) modified siRNA to survivin and cell permeable dominant negative survivin (SurR9-C84A) protein, led to downregulation of multidrug resistant (MDR) markers including survivin and induced drug sensitivity in sorted “cancer cells” as well as “cancer drug-resistant stem cells”. Our group also established orally administered nanocapsules/nanocarriers (NCs) encapsulated with super-paramagnetic iron oxide (Fe3O4)-saturated bovine lactoferrin (bLf) and zinc-ferrite saturated bLf (ZnxFe3-xO4-bLf) as theranostics for real-time live imaging in colon, prostate and breast tumours developed and atherosclerosis.

ARTHERITIS: Development of inflamed joints targeted by nanocapsules for the treatment of rheumatoid arthritis. Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that causes painful joint inflammation. RA is also referred to as a systemic illness that affects multiple organs such as lungs, eyes and if poorly treated leads to permanent joint damage, deformity, loss of function and disability. RA is incurable and poses a significant health burden in terms of personal, social and economic losses in Australia and worldwide. Current anti-RA drugs have severe side effects. There is presently an unmet need for a safe drug that is disease modifying and targets joint inflammatory disease progression. Recently, we designed, tested and patented biodegradable, non-toxic nanocapsules/nanocarriers (NCs) as a smart oral drug delivery system (Kanwar JR & Kanwar RK. “Nanoparticle” patent WO2012/145801).
 

CORNEAL HAZE/SCARRING: Corneal haze also known as scarring is caused by microbial infections, dry eyes, contact lenses, chemical trauma, physical agents, recent trend of “refractive laser surgery” and accidents including terrorism and wars. It is one of the leading cause of global blindness according to a recent World Health Organization report. In addition, infections such as trachoma, a chronic keratoconjunctivitis caused by Chlamydia trachomatis, which leads to haze/scarring and blinding, is an endemic in Australia, particularly in indigenous people and remote communities. Scarring is also a major issue after all types of surgeries and injuries due to TGF-β induction from the above mentioned conditions, that transform normal transparent corneal keratocytes into cloudy myofibroblast cells which overexpress survivin and α-smooth muscle actin (α-SMA). Recently we fabricated ultra-small algal chitosan nanoparticles (US CS NPs) for efficient delivery of Trichostatin-A (TSA) and cell permeable recombinant dominant-negative survivin protein tagged with poly-arginine (R9 carrier peptide) named SurR9-C84A, and bovine lactoferrin (bLf) to ocular tissues through topical administration to prevent carbendazim-induced toxicity. US CS NPs could be explored for their potential for delivering various ocular drugs through topical administration for other eye diseases including cataract, glaucoma and age-related macular degeneration. After the award of NHMRC grant on “corneal haze” we developed models for haze, glaucoma and age-related macular degeneration (AMD) and cataract.

DEVICES FOR DELIVERY AND DIAGNOSIS: Recently our group is focused on exploiting various Lab-on-a-Chip, or Microfluidic devices used in biomedical diagnostics for cancer, infectious, inflammatory diseases.

Conferences

National and international recognition: Invited speaker/conference chair/ conference organizing: Reflecting the recognition of Prof. Kanwar’s contribution to the biomedical research, he has been invited to national and international scientific meetings as a keynote speaker, for plenary lecture and/or symposium Chair or co-chair in more than 45 international conferences held in US, Australia, China, India, Iran, Hong Kong, UK and Singapore, in the last 5 years. Prof. Kanwar has organized more than 28 conferences in the field of nanomedicine, nanotechnology, immunology, cancer and biotechnology. In 2015 and 2016, he is organizing 3 new conferences on nanomedicine, pharmacology and biotechnology.

Professional activities

Professional involvement: He was invited for “Australian Science meets Policymakers”, Canberra and for the Integrative Medicine Education and Research (IMER) Group. Editorial Board role for 32 journals & Manuscript Reviewer for >120. He is the member of over 48 scientific committees and societies including American Chemical Society (ACS), American Association for Cancer Research (AACR), Australasian Society for Immunology (ASI), Australasian Integrative Medicine Association (AIMA), American Association of Nanomedicine, American Nano-Society, Australian Centre for Nanomedicine (UNSW), British Society for Nanomedicine, American Dairy Science Association, International Society of Aptamers (INSOAP) and The Australian Nanotechnology Network.

Teaching Interests:
Prof. Kanwar has supervised 5 Honours, 5 Master of Science and 15 Ph.D. students to graduation.  Currently, he has 4 visiting researchers, 8 Ph.D. students under his guidance, and provides co-supervision to 18 Ph.D. students. These students are working in exploring the roles of molecular mediators/cellular communication in the pathophysiological mechanisms of cancers (colon. breast, liver and brain) and chronic inflammatory diseases and devising their treatments, diagnostic biomarkers in the area of nanobiotechnology at Deakin, Australia, Deakin India Research Initiative (DIRI) in India. Several of these students have won conference presentation awards and international fellowships.

Professor Kanwar is also the unit chair for Innovations in Medical Biotechnology course.
• Innovations in Medical Biotechnology in Faculty of Health for 2 years HMM302.
• SEK320 - Nanobiotechnology - SEK320_TRI-1_2012

Media appearances

http://www.deakin.edu.au/research/stories/2012/06/25/the-fight-against-cancer
http://www.deakin.edu.au/itri/biodeakin/news/2011/02/01/biodeakin-researchers-receive-international-funding-to-develop-novel-anti-cancer-agent-and-anti-microbials
http://www.deakin.edu.au/research/stories/2010/05/13/deakins-research-pitch-in-india-continues-to-grow
http://www.deakin.edu.au/research/stories/2009/12/01/good-old-milk-as-a-cure-for-cancer
http://www.gsdm.com.au/newsletters/deakin/April09/4.html
http://www.gsdm.com.au/newsletters/deakin/dec09/6.html

Awards

Professor Kanwar has published more than 175 peer-reviewed original research papers. His papers in Gene Therapy, Journal of National Cancer Institute (JNCI) and Cancer Research have been cited 194, 137 and 82 times respectively. Prof Kanwar’s research is of high quality and highly relevant: 25 of his peer-reviewed publications have been cited more than 450 times till date. He has attracted AU$ 6 million in grant funding from Government funding agencies and AU$ 2.5 million from private funding agencies. His work has generated 12 patents/PCTs. Five of these patents have been licensed for commercialisation to biotech companies Antisoma, UK; Neurenpharma and NeuronZ, NZ. His research findings led to the development of novel ice-cream product ‘ReCharge’ with bovine lactoferrin and iron saturated milk lactoferrin as key ingredient and designated as the first medical food. It is showing promising results in phase II clinical trials for combating drug induced immunosuppression and gut damage in patients undergoing anticancer chemotherapy. One of his anti-cancer drug (anti-vascular DMXAA) is in the Sigma catalogue. He has been invited as a speaker in over 45 conferences and chaired several sessions on Immunology, Nanotechnology, Nanomedicine and Biotechnology. CIA' and his team have extensive experience in animal models and cancer biology. He has provided consultancies to more than 8 BioPharma companies including New Zealand Dairy Board, NeuronZ & Fonterra Corporation Limited, Auckland, New Zealand, Interpath Pty Ltd Australia, The Warrnambool Cheese & Butter Factory Company Limited, and 3 Indian Biotechnology based companies.

PATENTS
Web link: Patents weblink
(search for "Applicant name" Jagat Kanwar/Rupinder Kanwar)
1. WO2012145801 (NANOPARTICLE)
2. WO2006/054908
3. WO 2008/140335
4. WO 2008/079030
5. WO 2000/076497
6. WO 2002/030447
7. WO 2002/030448
8. WO 2004/009131
9. WO 2007/055599
10. WO 2006/112739
11. WO 2006/112738
12. WO 2005/107736

Projects

  1. Molecular regulation of survivin targeted nano-therapy in advanced colon, breast and prostate cancer
  2. Neem plant based Nano-Biopesticide and targeting cancers
  3. Nanoparticle encapsulated bacteriophage for the treatment of Salmonella infection
  4. Development in vitro and in vivo models for treatment of Aged macular degeneration
  5. Anti-cancer activities of dominant negative survivin (in the form of a nanoparticles), an alternative treatment for colon cancer
  6. Novel ophthalmic topical formulation targeting molecular pathogenesis of corneal haze
  7. Multi-targeted nanomedicine based therapy for treating corneal haze and cataract

Publications

Filter by

2017

In vitro and in vivo assessment of docetaxel formulation developed for esophageal stents

M Shaikh, H Zhang, H Wang, X Guo, Y Song, J Kanwar, S Garg

(2017), Vol. 18, pp. 130-137, American association of pharmaceutical scientists pharmscitech, Berlin, Germany, C1

journal

Chasing the personalized medicine dream through biomarker validation in colorectal cancer.

H Patil, S Saxena, C Barrow, J Kanwar, A Kapat, R Kanwar

(2017), Vol. 22, pp. 111-119, Drug discovery today, Amsterdam, The Netherlands, C1

journal

SurR9C84A protects and recovers human cardiomyocytes from hypoxia induced apoptosis

A Ashok, J Kanwar, U Krishnan, R Kanwar

(2017), Vol. 350, pp. 19-31, Experimental cell research, Amsterdam, The Netherlands, C1

journal

In situ morphological assessment of apoptosis induced by Phaleria macrocarpa (Boerl.) fruit ethyl acetate fraction (PMEAF) in MDA-MB-231 cells by microscopy observation

N Kavitha, Y Chen, J Kanwar, S Sasidharan

(2017), Vol. 87, pp. 609-620, Biomedicine and pharmacotherapy, Amsterdam, The Netherlands, C1

journal

Targeted theranostics against solid cancer using metal bond milk protein and aptamers

S Chaudhary, R Kanwar, J Kanwar

(2017), Vol. 17, pp. 2100-2111, Current topics in medicinal chemistry, Bussum, The Netherlands, C1

journal

Phaleria macrocarpa (Boerl.) fruit induce G?/G? and G?/M cell cycle arrest and apoptosis through mitochondria-mediated pathway in MDA-MB-231 human breast cancer cell

N Kavitha, C Ein Oon, Y Chen, J Kanwar, S Sasidharan

(2017), Vol. 201, pp. 42-55, Journal ethnopharmacology, Amsterdam, The Netherlands, C1

journal

Polyalthia longifolia Methanolic Leaf Extracts (PLME) induce apoptosis, cell cycle arrest and mitochondrial potential depolarization by possibly modulating the redox status in hela cells

S Vijayarathna, C Oon, Y Chen, J Kanwar, S Sasidharan

(2017), Vol. 89, pp. 499-514, Biomedicine & pharmacotherapy, Amsterdam, The Netherlands, C1

journal

Standardized Polyalthia longifolia leaf extract (PLME) inhibits cell proliferation and promotes apoptosis: the anti-cancer study with various microscopy methods

S Vijayarathna, Y Chen, J Kanwar, S Sasidharan

(2017), Vol. 91, pp. 366-377, Biomedicine & pharmacotherapy, Issy les Moulineaux, France, C1

journal

Topical ophthalmic formulation of Trichostatin A and SurR9-C84A for quick recovery post-alkali burn of corneal haze

K Roy, C Cheung, R Kanwar, R Sandhir, J Kanwar

(2017), Vol. 8, pp. 1-15, Experimental pharmacology and drug discovery, Lausanne, Switzerland, C1

journal

Integrated 3D printed scaffolds and electrical stimulation for enhancing primary human cardiomyocyte cultures

S Adams, A Ashok, R Kanwar, J Kanwar, A Kouzani

(2017), Vol. 6, pp. 18-24, Bioprinting, Amsterdam, The Netherlands, C1

journal

Progress on azadirachta indica based biopesticides in replacing synthetic toxic pesticides

S Chaudhary, R Kanwar, A Sehgal, D Cahill, C Barrow, R Sehgal, J Kanwar

(2017), Vol. 8, pp. 1-13, Frontiers in plant science, Lausanne, Switzerland, C1

journal

Neocarzinostatin, aptamer conjugates for targeting EpCAM-positive tumor cells

P Athyala, J Kanwar, S Chitipothu, R Kanwar, S Krishnakumar, J Watson, J Narayanan

(2017), Vol. 37, pp. 3615-3629, Anticancer research, Kapandriti Attica, Greece, C1

journal

Argon gas plasma to decontaminate and extend shelf life of milk

S Ponraj, J Sharp, J Kanwar, A Sinclair, L Kviz, K Nicholas, X Dai

(2017), pp. 1-8, Plasma processes and polymers, Chichester, Eng., C1

journal
2016

Radioprotective activity of Polyalthia longifolia standardized extract against x-ray radiation injury in mice

S Jothy, T Saito, J Kanwar, Y Chen, A Aziz, L Yin-Hui, S Sasidharan

(2016), Vol. 32, pp. 150-161, Physica medica, Amsterdam, The Netherlands, C1

journal

Probing the biophysical interaction between Neocarzinostatin toxin and EpCAM RNA aptamer

P Athyala, J Kanwar, M Alameen, R Kanwar, S Krishnakumar, J Watson, U Vetrivel, J Narayanan

(2016), Vol. 469, pp. 257-262, Biochemical and biophysical research communications, Amsterdam, The Netherlands, C1

journal

Antiparasitic and immunomodulatory potential of oral nanocapsules encapsulated lactoferrin protein against plasmodium berghei

N Anand, R Kanwar, R Sehgal, J Kanwar

(2016), Vol. 11, pp. 47-62, Nanomedicine, London, Eng., C1

journal

Ultra-small algal chitosan ocular nanoparticles with iron-binding milk protein prevents the toxic effects of carbendazim pesticide

P Sunkireddy, R Kanwar, J Ram, J Kanwar

(2016), Vol. 11, pp. 495-511, Nanomedicine, London, Eng., C1

journal

Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells

K Roy, Y Patel, R Kanwar, R Rajkhowa, X Wang, J Kanwar

(2016), Vol. 11, pp. 25-44, International journal of nanomedicine, Macclesfield, Eng., C1

journal

Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents

R Chaudhary, K Roy, R Kanwar, K Walder, J Kanwar

(2016), Vol. 14, pp. 1-17, Journal of nanobiotechnology, London, Eng., C1

journal

Multimodal iron oxide (Fe?O?)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER-/PR-/HER2-)

J Kanwar, S Kamalapuram, S Krishnakumar, R Kanwar

(2016), Vol. 11, pp. 249-268, Nanomedicine, London, Eng., C1

journal

Comparative activities of milk components in reversing chronic colitis

J Kanwar, R Kanwar, S Stathopoulos, N Haggarty, A MacGibbon, K Palmano, K Roy, A Rowan, G Krissansen

(2016), Vol. 99, pp. 2488-2501, Journal of dairy science, Atlanta, Ga., C1

journal

Clinico-pathological association of delineated miRNAs in uveal melanoma with monosomy 3/Disomy 3 chromosomal aberrations

N Venkatesan, J Kanwar, P Deepa, V Khetan, T Crowley, R Raguraman, G Sugneswari, P Rishi, V Natarajan, J Biswas, S Krishnakumar

(2016), Vol. 11, pp. 1-14, PLoS one, San Francisco, Calif., C1

journal

Effect of polymer microstructure on the docetaxel release and stability of polyurethane formulation

M Shaikh, N Choudhury, R Knott, J Kanwar, S Garg

(2016), Vol. 101, pp. 82-89, European journal of pharmaceutics and biopharmaceutics, Amsterdam, The Netherlands, C1

journal

Exploration of the anticandidal mechanism of Cassia spectabilis in debilitating candidiasis

A Torey, S Vijayarathna, S Jothy, S Gothai, Y Chen, L Latha, J Kanwar, S Dharmaraj, S Sasidharan

(2016), Vol. 6, pp. 97-104, Journal of traditional and complementary medicine, Taipei, Taiwan, C1

journal

Multimodal nanomedicine strategies for targeting cancer cells as well as cancer stem cell signalling mechanisms

J Kanwar, R Samarasinghe, S Kamalapuram, R Kanwar

(2016), pp. 1-8, Mini reviews in medicinal chemistry, Beijing, China, C1

journal

Survivin modulators: an updated patent review (2011-2015)

K Roy, N Singh, R Kanwar, J Kanwar

(2016), Vol. 11, pp. 152-169, Recent patents on anti-cancer drug discovery, Beijing, China, C1

journal

Targeting HSP90/survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma

N Venkatesan, J Kanwar, P Deepa, S Navaneethakrishnan, C Joseph, S Krishnakumar

(2016), Vol. 252, pp. 141-149, Chemico-biological interactions, London, Eng., C1

journal

Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells

J Lee, C-W Kuo, S-L Tsai, S Cheng, S-H Chen, H-H Chan, C-H Lin, K-Y Lin, C-F Li, J Kanwar, E Leung, C Cheung, W-J Huang, Y-C Wang, C Cheung

(2016), Vol. 7, pp. 1-13, Frontiers in pharmacology, Lausanne, Switzerland, C1

journal

Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers

S Kamalapuram, R Kanwar, K Roy, R Chaudhary, R Sehgal, J Kanwar

(2016), Vol. 11, pp. 1349-1366, International journal of nanomedicine, Macclesfield, Eng., C1

journal

Targeting CD44, ABCG2 and CD133 markers using aptamers: in silico analysis of CD133 extracellular domain 2 and its aptamer

N Subramanian, B Akilandeswari, A Bhutra, M Alameen, U Vetrivel, V Khetan, R Kanwar, J Kanwar, S Krishnakumar

(2016), Vol. 6, pp. 32115-32123, RSC advances, Cambridge, Eng., C1

journal

Effects of Calophyllum inophyllum fruit extract on the proliferation and morphological characteristics of human breast cancer cells MCF-7

Shanmugapriya, Y Chen, J Kanwar, S Sasidharan

(2016), Vol. 6, pp. 291-297, Asian Pacific journal of tropical disease, Haikou, China, C1

journal

Amoebiasis vaccine development: a snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin

R Singh, A Walia, J Kanwar, J Kennedy

(2016), Vol. 91, pp. 258-268, International journal of biological macromolecules, Amsterdam, The Netherlands, C1

journal

Protozoa lectins and their role in host-pathogen interactions

R Singh, A Walia, J Kanwar

(2016), Vol. 34, pp. 1018-1029, Biotechnology advances, Amsterdam, The Netherlands, C1

journal

Studies to prevent degradation of recombinant fc-fusion protein expressed in mammalian cell line and protein characterization

S Chakrabarti, C Barrow, R Kanwar, V Ramana, J Kanwar

(2016), Vol. 17, pp. 1-22, International journal of molecular sciences, Basel, Switzerland., C1

journal

A study of gene expression of survivin, its antiapoptotic variants, and targeting survivin in vitro for therapy in retinoblastoma

J Samuel, R Kanwar, J Kanwar, V Khetan, S Krishnakumar

(2016), Vol. 38, pp. e230-e242, Journal of pediatric hematology/oncology, Philadelphia, Pa., C1

journal

Evaluation of the cytotoxicity, cell-cycle arrest, and apoptotic induction by Euphorbia hirta in MCF-7 breast cancer cells

Y Kwan, T Saito, D Ibrahim, F Al-Hassan, C Ein Oon, Y Chen, S Jothy, J Kanwar, S Sasidharan

(2016), Vol. 54, pp. 1223-1236, Pharmaceutical biology, Abingdon, Eng., C1

journal

Doxorubicin conjugated to immunomodulatory anticancer lactoferrin displays improved cytotoxicity overcoming prostate cancer chemo resistance and inhibits tumour development in TRAMP mice

J Shankara Narayanan, J Kanwar, A Al-Juhaishi, R Kanwar

(2016), Vol. 6, pp. 1-16, Scientific reports, London, Eng., C1

journal

Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry-based imaging

N Subramanian, A Srimany, J Kanwar, R Kanwar, B Akilandeswari, P Rishi, V Khetan, M Vasudevan, T Pradeep, S Krishnakumar

(2016), Vol. 5, pp. 1-11, Molecular therapy : nucleic acids, Amsterdam, The Netherlands, C1

journal

Nanotheranostic based iron oxide (Fe?O?) saturated lactoferrin nanocapsules for colonic adenocarcinoma

S Kamalapuram, R Kanwar, J Kanwar

(2016), Vol. 12, pp. 1758-1773, Journal of biomedical nanotechnology, Valencia, Calif., C1

journal

E-cadherin aptamer-conjugated delivery of doxorubicin for targeted inhibition of prostate cancer cells

R Chaudhary, K Roy, R Kanwar, R Veedu, S Krishnakumar, C Cheung, A Verma, J Kanwar

(2016), Vol. 69, pp. 1108-1116, Australian journal of chemistry, Clayton, Vic., C1

journal

Mushroom lectins as promising anticancer substances

R Singh, H Kaur, J Kanwar

(2016), Vol. 17, pp. 797-807, Current protein & peptide science, Beijing, China, C1

journal

Redox control of antioxidant and antihepatotoxic activities of Cassia surattensis seed extract against paracetamol intoxication in mice: in vitro and in vivo studies of herbal green antioxidant

U Uthaya Kumar, Y Chen, J Kanwar, S Sasidharan

(2016), Vol. 2016, pp. 1-13, Oxidative medicine and cellular longevity, Cairo, Egypt, C1

journal

Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry-based imaging.

Nithya Subramanian, Amitava Srimany, Jagat Kanwar, Rupinder Kanwar, Balachandran Akilandeswari, Pukhraj Rishi, Vikas Khetan, Madavan Vasudevan, Thalappil Pradeep, Subramanian Krishnakumar

(2016), Vol. 5, pp. e358-, Mol Ther Nucleic Acids, United States, C1

journal
2015

Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc

J Kanwar, V Mahidhara, K Roy, S Sasidharan, S Krishnakumar, N Prasad, R Sehgal, R Kanwar

(2015), Vol. 10, pp. 35-55, Nanomedicine, London, United Kingdom, C1

journal

Lactoferrin induced neuronal differentiation: A boon for brain tumours.

B Sriramoju, R Kanwar, J Kanwar

(2015), Vol. 41, pp. 28-36, International Journal of Developmental Neuroscience, England, C1

journal

YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

S Cheng, Y Chang, C Liu, J Lee, H Chan, C Kuo, K Lin, S Tsai, S Chen, C Li, E Leung, J Kanwar, C Huang, J Chang, C Cheung

(2015), Vol. 172, pp. 214-234, British journal of pharmacology, London, Eng., C1

journal

Blocking the maturation of OncomiRNAs using pri-miRNA-17?92 aptamer in retinoblastoma

N Subramanian, J Kanwar, R Kanwar, S Krishnakumar

(2015), Vol. 25, pp. 47-52, Nucleic acid therapeutics, New Rochelle, N. Y., C1

journal

Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

K Roy, R Kanwar, S Krishnakumar, C Cheung, J Kanwar

(2015), Vol. 10, pp. 1019-1043, International journal of nanomedicine, Auckland, N. Z., C1

journal

Nucleic acid-based aptamers: applications, development and clinical trials

J Kanwar, K Roy, N Maremanda, K Subramanian, R Veedu, R Bawa, R Kanwar

(2015), Vol. 22, pp. 2539-2557, Current medicinal chemistry, Bussum, The Netherlands, C1

journal

Nanoformulated mutant SurR9-C84A: a possible key for alzheimer's and its associated inflammation

B Sriramoju, R Kanwar, J Kanwar

(2015), Vol. 32, pp. 2787-2797, Pharmaceutical research, New York, N. Y., C1

journal

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

N Subramanian, J Kanwar, P Athalya, N Janakiraman, V Khetan, R Kanwar, S Eluchuri, S Krishnakumar

(2015), Vol. 22, pp. 1-10, Journal of biomedical science, London, Eng., C1

journal

Evaluation of nanoformulated therapeutics in an ex-vivo bovine corneal irritation model

B Sriramoju, K Roy, R Kanwar, J Kanwar

(2015), Vol. 29, pp. 917-925, Toxicology in vitro, Amsterdam, The Netherlands, C1

journal

Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases

B Sriramoju, R Kanwar, R Veedu, J Kanwar

(2015), Vol. 15, pp. 1115-1124, Current topics in medicinal chemistry, Bussum, The Netherlands, C1

journal

Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy

K Roy, R Kanwar, C Antonio Cheung, C Lee Fleming, R Veedu, S Krishnakumar, J Kanwar

(2015), Vol. 5, pp. 29008-29016, RSC advances, Cambridge, Eng., C1

journal

Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery

N Subramanian, J Kanwar, B Akilandeswari, R Kanwar, V Khetan, S Krishnakumar

(2015), Vol. 51, pp. 6940-6943, Chemical communications, Cambridge, Eng., C1

journal

MicroRNAs: association with radioresistant and potential uses of natural remedies as green gene therapeutic approaches

S Jothy, Y Chen, S Vijayarathna, J Kanwar, S Sasidharan

(2015), Vol. 15, pp. 15-20, Current gene therapy, Beijing, China, C1-1

journal

Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer

J Gibbons, J Kanwar, R Kanwar

(2015), Vol. 15, pp. 1-16, BMC cancer, London, Eng., C1

journal

Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions

J Kanwar, K Roy, Y Patel, S-F Zhou, M Singh, D Singh, M Nasir, R Sehgal, A Sehgal, R Singh, S Garg, R Kanwar

(2015), Vol. 20, pp. 9703-9731, Molecules, Basel, Switzerland, C1-1

journal

Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition

S Edwards, V Poongavanam, J Kanwar, K Roy, K Hillman, N Prasad, R Leth-Larsen, M Petersen, M Maru?i?, J Plavec, J Wengel, R Veedu

(2015), Vol. 51, pp. 9499-9502, Chemical Communications, London, Eng., C1

journal

Inflammatory bowel disease: pathogenesis, causative factors, issues, drug treatment strategies, and delivery approaches

D Singh, S Srivastava, M Pradhan, J Kanwar, M Singh

(2015), Vol. 32, pp. 181-214, Critical reviews in therapeutic drug carrier systems, Danbury, Conn., C1-1

journal

Cissus quadrangularis inhibits IL-1? induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling

J Kanwar, R Samarasinghe, K Kumar, R Arya, S Sharma, S Zhou, S Sasidharan, R Kanwar

(2015), Vol. 9, pp. 2927-2940, Drug Design, Development and Therapy, [Auckland, N.Z.], C1

journal

Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism

G Mahidhara, R Kanwar, K Roy, J Kanwar

(2015), Vol. 10, pp. 4081-4098, International journal of nanomedicine, Auckland, N. Z., C1

journal

EpCAM Aptamer-siRNA chimera targets and regress epithelial cancer

N Subramanian, J Kanwar, R Kanwar, J Sreemanthula, J Biswas, V Khetan, S Krishnakumar

(2015), Vol. 10, pp. 1-19, PLoS one, San Francisco, Calif., C1

journal

Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: promising potential for targeting radiosensitive retinoblastoma

J Samuel, N Singh, J Kanwar, S Krishnakumar, R Kanwar

(2015), Vol. 139, pp. 108-114, Experimental eye research, Amsterdam, The Netherlands, C1

journal

Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite-host interaction

N Anand, R Kanwar, M Dubey, R Vahishta, R Sehgal, A Verma, J Kanwar

(2015), Vol. 9, pp. 3821-3835, Drug design develeopment and therapy, Auckland, N.Z, C1

journal

Brain targeted PLGA nanocarriers alleviating amyloid-? expression and preserving basal survivin in degenerating mice model

B Sriramoju, P Neerati, R Kanwar, J Kanwar

(2015), Vol. 1852, pp. 2423-2431, Biochimica et biophysica acta, Amsterdam, The Netherlands, C1

journal

LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging

K Roy, R Kanwar, J Kanwar

(2015), Vol. 71, pp. 84-99, Biomaterials, Amsterdam, The Netherlands, C1

journal

Molecular targets in arthritis and recent trends in nanotherapy

K Roy, R Kanwar, J Kanwar

(2015), Vol. 10, pp. 5407-5420, International journal of nanomedicine, Auckland, N. Z., C1

journal

Targeting cancer cells using LNA-modified aptamer-siRNA chimeras

N Subramanian, J Kanwar, R Kanwar, S Krishnakumar

(2015), Vol. 25, pp. 317-322, Nucleic acid therapeutics, New Rochelle, N.Y., C1

journal

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

N Anand, R Sehgal, R Kanwar, M Dubey, R Vasishta, J Kanwar

(2015), Vol. 10, pp. 6355-6369, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Neurobehavioral burden of multiple sclerosis with nanotheranostics

B Sriramoju, R Kanwar, J Kanwar

(2015), Vol. 11, pp. 2675-2689, Neuropsychiatric disease and treatment, Auckland, New Zealand, C1

journal

Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells

N Maremanda, K Roy, R Kanwar, V Shyamsundar, V Ramshankar, A Krishnamurthy, S Krishnakumar, J Kanwar

(2015), Vol. 9, pp. 1-20, Biomicrofluidics, Maryland, United States, C1

journal

Role of nanomedicine in arthritic disorders

R Samarasinghe, R Kanwar, J Kanwar

(2015), Vol. 1, pp. 281-311, NanoBioMedicine Vol. 1: Nanomedicine, Houston, Tex., B1-1

chapter

Can cancer therapy be achieved by bridging apoptosis and autophagy: A method based on microRNA-dependent gene therapy and phytochemical targets

S Vijayarathna, S Gothai, S Jothy, Y Chen, J Kanwar, S Sasidharan

(2015), Vol. 16, pp. 7435-7439, Asian pacific journal of cancer prevention, Bangkok, Asia, C1

journal
2014

Current protein-based anti-angiogenic therapeutics

S Chakrabarti, C Barrow, R Kanwar, V Ramana, J Kanwar

(2014), Vol. 14, pp. 291-312, Mini-reviews in medicinal chemistry, Bussum, The Netherlands, C1

journal

Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases

J Kanwar, J Shankaranarayanan, S Gurudevan, R Kanwar

(2014), Vol. 19, pp. 1309-1321, Drug discovery today, Amsterdam, The Netherlands, C1

journal

Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers

R Samarasinghe, R Kanwar, K Kumar, J Kanwar

(2014), Vol. 9, pp. 819-837, Nanomedicine, London, England, C1

journal

The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis

R Samarasinghe, R Kanwar, J Kanwar

(2014), Vol. 35, pp. 7522-7534, Biomaterials, Amsterdam, The Netherlands, C1

journal

Fabrication of boron nitride nanotube-gold nanoparticle hybrids using pulsed plasma in liquid

S Ponraj, Z Chen, L Li, J Shankaranarayanan, G Rajmohan, J du Plessis, A Sinclair, Y Chen, X Wang, J Kanwar, X Dai

(2014), Vol. 30, pp. 10712-10720, Langmuir, Washington, DC, C1

journal

Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf)

F Ebrahim, J Shankaranarayanan, J Kanwar, S Gurudevan, U Krishnan, R Kanwar

(2014), Vol. 9, pp. 1-13, PLoS One, San Francisco, CA, C1

journal

Nanomedicine based nanoparticles for neurological disorders

B Sriramoju, R Kanwar, J Kanwar

(2014), Vol. 21, pp. 4154-4168, Current medicinal chemistry, Bussum, Netherlands, C1

journal

Nanoformulated cell-penetrating survivin mutant and its dual actions

B Sriramoju, R Kanwar, J Kanwar

(2014), Vol. 9, pp. 3279-3298, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies

Z-X Wang, J Sun, C Howell, Q-Y Zhou, Z-X He, T Yang, H Chew, W Duan, Z-W Zhou, J Kanwar, S-F Zhou

(2014), Vol. 28, pp. 551-582, Fundamental and clinical pharmacology, Chichester, England, C1

journal

MicroRNA pathways : an emerging role in identification of therapeutic strategies

S Vijayarathna, C Oon, S Jothy, Y Chen, J Kanwar, S Sasidharan

(2014), Vol. 14, pp. 112-120, Current Gene Therapy, Bussum, Netherlands, C1

journal

A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells

N Subramanian, J Sreemanthula, B Balaji, J Kanwar, J Biswas, S Krishnakumar

(2014), Vol. 50, pp. 11810-11813, Chemical Communications, Cambridge, England, C1

journal

Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers

N Singh, S Krishnakumar, R Kanwar, C Cheung, J Kanwar

(2014), Vol. 20, pp. 578-587, Drug discovery today, London, Eng., C1

journal

Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism.

I Gupta, R Sehgal, R Kanwar, V Punj, J Kanwar

(2014), pp. 1-26, Nanomedicine, London, United Kingdom, C1

journal

Bioceramic nanomaterials in medical applications

J Kanwar, G Mahidhara, K Roy, R Kanwar

(2014), pp. 163-175, Bioengineered nanomaterials, Boca Raton, Flo., B1

chapter
2013

Generating different profiles of gradient concentrations inside a gel-filled chamber : design and simulation

M Tehranirokh, A Kouzani, P Francis, J Kanwar

(2013), Vol. 19, pp. 623-628, Microsystem technologies, Berlin, Germany, C1

journal

Survivin signaling in clinical oncology : a multifaceted dragon

J Kanwar, S Kamalapuram, R Kanwar

(2013), Vol. 33, pp. 765-789, Medicinal research reviews, London, England, C1

journal

Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer

R Kanwar, J Kanwar

(2013), Vol. 20, pp. 450-458, Protein & peptide letters, Bussum, The Netherlands, C1

journal

Synthesis and biological evaluation of novel folic acid receptor-targeted, ?-cyclodextrin-based drug complexes for cancer treatment

J Yin, S Sharma, S Shumyak, Z Wang, Z Zhou, Y Zhang, P Guo, C Li, J Kanwar, T Yang, S Mohapatra, W Liu, W Duan, J Wang, Q Li, X Zhang, J Tan, L Jia, J Liang, M Wei, X Li, S Zhou

(2013), Vol. 8, pp. 1-20, PLOS one, San Francisco, California, C1

journal

Microfluidic devices for cell cultivation and proliferation

M Tehranirokh, A Kouzani, P Francis, J Kanwar

(2013), Vol. 7, pp. 1-32, Biomicrofluidics, Melville, N.Y., C1

journal

Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer.

S Gurudevan, R Kanwar, R Veedu, S Sasidharan, R Kennedy, K Walder, N Prasad, J Kanwar

(2013), Vol. 13, pp. 322-334, Current gene therapy, Bussum, The Netherlands, C1

journal

Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers

S Dawar, N Singh, R Kanwar, R Kennedy, R Veedu, S Zhou, S Krishnakumar, S Hazra, S Sasidharan, W Duan, J Kanwar

(2013), Vol. 18, pp. 1292-1300, Drug discovery today, London, England, C1

journal

RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma

N Subramanian, S Navaneethakrishnan, J Biswas, R Kanwar, J Kanwar, S Krishnakumar

(2013), Vol. 8, PLoS One, San Francisco, CA, C1

journal

Curcumin regulates colon cancer by inhibiting p-glycoprotein in in-situ cancerous colon perfusion rat model

P Neerati, Y Sudhakar, J Kanwar

(2013), Vol. 5, pp. 313-319, Journal of cancer science and therapy, Los Angeles, Calif., C1-1

journal

Natural antioxidant biomolecules promises future nanomedicine based therapy for cataract

P Sunkireddy, S Jha, J Kanwar, S Yadav

(2013), Vol. 112, pp. 554-562, Colloids and surfaces b: biointerfaces, Amsterdam, The Netherlands, C1-1

journal

Evaluation of the genotoxic potential against H2O2-radical-mediated DNA damage and acute oral toxicity of standardized extract of Polyalthia longifolia leaf

S Jothy, Y Chen, J Kanwar, S Sasidharan

(2013), Evidence-based complementary and alternative medicine, Cairo, Egypt, C1-1

journal

Treat cancers by targeting survivin: just a dream or future reality?

M Coumar, F-Y Tsai, J Kanwar, S Sarvagalla, C Cheung

(2013), Vol. 39, pp. 802-811, Cancer treatment reviews, Amsterdam, The Netherlands, C1-1

journal

Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology

R Tannenberg, H Shamaileh, L Lauridsen, J Kanwar, P Dodd, R Veedu

(2013), Vol. 10, pp. 442-448, Current Alzheimer research, Beijing, China, C1-1

journal

Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

P Xiu, X Dong, X Dong, Z Xu, H Zhu, F Liu, Z Wei, B Zhai, J Kanwar, H Jiang, J Li, X Sun

(2013), Vol. 104, pp. 375-382, Cancer science, Chichester, Eng., C1-1

journal
2012

Milk proteins and human health

J Kanwar, R Kanwar, M Puri

(2012), pp. 1-1, Food biotechnology : principles and practices, New Delhi, India, B1-1

chapter

Structure, rhelogy and texturization of food proteins

M Puri, P Pahuja, J Kanwar

(2012), pp. 1-1, Food biotechnology : principles and practices, India, B1-1

chapter

Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer

L Ma, H Qiao, C He, Q Yang, C Cheung, J Kanwar, X Sun

(2012), Vol. 30, pp. 508-517, Investigational new drugs, New York, N.Y., C1

journal

A novel nanoplatform for oral delivery of anti-cancer biomacromolecules

G Mahidhara, G Mahidhara, R Kanwar, R Kanwar, J Kanwar, J Kanwar

(2012), Vol. 9, pp. 942-960, International journal of nanotechnology, Olney, England, C1

journal

Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells

J Kanwar, R Kanwar, G Mahidhara, H Cheung

(2012), Vol. 65, pp. 5-14, Australian journal of chemistry, Collingwood, VIC., C1

journal

Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide

J Kanwar, J Gibbons, A Verma, R Kanwar

(2012), Vol. 23, pp. 471-482, Anti-cancer drugs, Philadelphia, Pa., C1

journal

Gradient generating microfluidic devices for cell cultivation

M Tehrani-Rokh, A Kouzani, J Kanwar

(2012), Vol. 29, pp. 1740-1744, Procedia engineering, Amsterdam, Netherlands, C1

journal

Herb-drug interactions and mechanistic and clinical considerations

X Chen, K Sneed, S Pan, C Cao, J Kanwar, H Chew, S Zhou

(2012), Vol. 13, pp. 640-651, Current drug metabolism, Hilversum, The Netherlands, C1

journal

The antimicrobial efficacy of elaeis guineensis : characterization, in Vitro and in Vivo studies

S Vijayarathna, Z Zakaria, Y Chen, L Latha, J Kanwar, S Sasidharan

(2012), Vol. 17, pp. 4860-4877, Molecules, Basel, Switzerland, C1

journal

Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis : how far have we come?

R Kanwar, R Chaudhary, T Tsuzuki, J Kanwar

(2012), Vol. 7, pp. 899-916, Nanomedicine, London, England, C1

journal

Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages

R Kanwar, R Chaudhary, T Tsuzuki, J Kanwar

(2012), Vol. 7, pp. 735-749, Nanomedicine, London, England, C1

journal

Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer

N Subramanian, V Raghunathan, J Kanwar, R Kanwar, S Elchuri, V Khetan, S Krishnakumar

(2012), Vol. 18, pp. 2783-2795, Molecular vision, Atlanta, Ga., C1

journal

Nanotechnology based platforms for survivin targeted drug discovery

R Samarasinghe, J Gibbons, R Kanwar, J Kanwar

(2012), Vol. 7, pp. 1083-1092, Expert opinion on drug discovery, London, England, C1

journal

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

J Kanwar, B Sriramoju, R Kanwar

(2012), Vol. 7, pp. 3259-3278, International journal of nanomedicine, Auckland, New Zealand, C1

journal

Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy

J Kanwar, G Mahidhara, R Kanwar

(2012), Vol. 7, pp. 1521-1550, Nanomedicine, London, England, C1

journal

The role of nanomedicine in cell based therapeutics in cancer and inflammation.

R Samarasinghe, R Kanwar, J Kanwar

(2012), Vol. 1, pp. 133-144, International journal of molecular and cellular medicine, Babol, Iran, C1-1

journal

Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases

J Kanwar, R Samarasinghe, R Sehgal, R Kanwar

(2012), Vol. 4, pp. 31-42, Journal of cancer science & therapy, Westlake, Calif., C1-1

journal

TH17 cells in cancer related inflammation

R Kanwar, J Kanwar

(2012), pp. 43-60, Recent advances in immunology to target cancer, inflammation and infections, Rijeka, Croatia, B1-1

chapter

Immunology of Leishmaniasis and future prospective of vaccines

R Sehgal, K Goyal, R Kanwar, A Sehgal, J Kanwar

(2012), pp. 479-494, Recent advances in immunology to target cancer, inflammation and infections, Rijeka, Croatia, B1-1

chapter

Evaluation of the hepatoprotective effects of Lantadene A, a pentacyclic triterpenoid of Lantana plants against acetaminophen-induced liver damage

C Grace-Lynn, Y Chen, L Latha, J Kanwar, S Jothy, S Vijayarathna, S Sasidharan

(2012), Vol. 17, pp. 13937-13947, Molecules, Basel, Switzerland, C1-1

journal
2011

Antiangiogenic therapy using nanotechnological-based delivery system

J Kanwar, G Mahidhara, R Kanwar

(2011), Vol. 16, pp. 188-202, Drug discovery today, London, England, C1

journal

Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)

S He, S Li, J Kanwar, S Zhou

(2011), Vol. 18, pp. 439-481, Current medicinal chemistry, Bussum, Netherlands, C1

journal

Receptor mediated tumor targeting : an emerging approach for cancer therapy

C Mohanty, M Das, J Kanwar, S Sahoo

(2011), Vol. 8, pp. 45-58, Current drug delivery, Bussum, Netherlands, C1

journal

Viral RNA silencing suppressors (RSS) : novel strategy of viruses to ablate the host RNA interference (RNAi) defense system

S Bivalkar-Mehla, J Vakharia, R Mehla, M Abreha, J Kanwar, A Tikoo, A Chauhan

(2011), Vol. 155, pp. 1-9, Virus research, Amsterdam, Netherlands, C1

journal

Lactoferrin and cancer in different cancer models

J Gibbons, R Kanwar, J Kanwar

(2011), Vol. S3, pp. 1080-1088, Frontiers in Bioscience, Albertson, N.Y., C1

journal

Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity

S Baratchi, R Kanwar, J Kanwar

(2011), Vol. 233, pp. 18-28, Journal of neuroimmunology, Amsterdam, Netherlands, C1

journal

Structure and properties of biomedical films prepared from aqueous and acidic silk fibroin solutions

R Rajkhowa, B Levin, S Redmond, L Li, L Wang, J Kanwar, M Atlas, X Wang

(2011), Vol. 97A, pp. 37-45, Journal of biomedical materials research : Part A, Hoboken, N.J., C1

journal

Molecular weight and secondary structure change in eri silk during alkali degumming and powdering

R Rajkhowa, L Wang, J Kanwar, X Wang

(2011), Vol. 119, pp. 1339-1347, Journal of applied polymer science, Hoboken, N. J., C1

journal

Antioxidant enzyme activities of iron-saturated bovine lactoferrin (Fe-bLf) in human gut epithelial cells under oxidative stress

H Burrow, R Kanwar, J Kanwar

(2011), Vol. 7, pp. 224-230, Medicinal chemistry, Bussum, Netherlands, C1

journal

Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress

S Baratchi, R Kanwar, J Kanwar

(2011), Vol. 6, pp. 1-8, PLoS ONE, San Francisco, Ca., C1

journal

Targeting survivin in cancer : the cell-signalling perspective

J Kanwar, J Kanwar, S Kamalapuram, S Kamalapuram, R Kanwar, R Kanwar

(2011), Vol. 16, pp. 485-494, Drug Discovery Today, London, United Kingdom, C1

journal

Nanoparticles in the treatment and diagnosis of neurological disorders : untamed dragon with fire power to heal

J Kanwar, X Sun, V Punj, B Sriramoju, R Mohan, S Zhou, A Chauhan, R Kanwar

(2011), Vol. 8, pp. 399-414, Nanomedicine : nanotechnology, biology and medicine, Philadelphia, Pa., C1

journal

Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma

J Kanwar, N Singh, R Kanwar

(2011), Vol. 6, pp. 701-714, Nanomedicine, London, England, C1

journal

Targeting hepatitis B virus and human papillomavirus induced carcinogenesis : novel patented therapeutics

R Kanwar, N Singh, S Gurudevan, J Kanwar

(2011), Vol. 6, pp. 158-174, Recent patents on anti-infective drug discovery, Bussum, Netherlands, C1

journal

The use of cyclodextrins nanoparticles for oral delivery

J Kanwar, B Long, R Kanwar

(2011), Vol. 18, pp. 2079-2085, Current medicinal chemistry, Hilversum, The Netherlands, C1

journal

Toll like receptors play a role in general immunity, eye infection and inflammation : TLRs for nanodelivery

J Kanwar, S Zhou, S Gurudevan, C Barrow, R Kanwar

(2011), Vol. 2, pp. 1-10, Journal of clinical and cellular immunology, Los Angeles, Calif., C1

journal

Chimeric aptamers in cancer cell-targeted drug delivery

J Kanwar, K Roy, R Kanwar

(2011), Vol. 46, pp. 459-477, Critical reviews in biochemistry and molecular biology, London, England, C1

journal

Effect of selenium-saturated bovine lactoferrin (Se-bLF) on antioxidant enzyme activities in human gut epithelial cells under oxidative stress

H Burrow, R Kanwar, G Mahidhara, J Kanwar

(2011), Vol. 11, pp. 762-771, Anti-cancer agents in medicinal chemistry, Bussum, Netherlands, C1

journal

Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats

G Tan, S Pan, J Li, X Dong, K Kang, M Zhao, X Jiang, J Kanwar, H Qiao, H Jiang, X Sun

(2011), Vol. 6, pp. 1-10, Plos one, San Francisco, Calif., C1

journal

Mitomycin C: a promising agent for the treatment of canine corneal scarring

R Gupta, B Yarnall, E Giuliano, J Kanwar, D Buss, R Mohan

(2011), Vol. 14, pp. 304-312, Veterinary ophthalmology, London, England, C1-1

journal
2010

Cell disruption optimization and covalent immobilization of beta-D-galactosidase from kluyveromyces marxianus YW-1 for lactose hydrolysis in milk

M Puri, S Gupta, P Pahuja, A Kaur, J Kanwar, J Kennedy

(2010), Vol. 160, pp. 98-108, Applied biochemistry and biotechnology, Totowa, United States, C1

journal

Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice

H Jiang, W Tao, M Zhang, S Pan, J Kanwar, X Sun

(2010), Vol. 28, pp. 74-84, Cancer investigation, New York, N.Y., C1

journal

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells

C Cheung, H Chen, L Cheng, K Lyu, J Kanwar, J Chang

(2010), Vol. 9, pp. 1-11, Molecular cancer, London, England, C1

journal

Survivin : a target from brain cancer to neurodegenerative disease

S Baratchi, R Kanwar, J Kanwar

(2010), Vol. 45, pp. 535-554, Critical reviews in biochemistry and molecular biology, London, England, C1

journal

Targeting survivin in cancer : patent review

J Kanwar, S Kamalapuram, R Kanwar

(2010), Vol. 20, pp. 1723-1737, Expert opinion on therapeutic patents, London, England, C1

journal

Therapeutic effects of matrine on primary and metastatic breast cancer

H Li, G Tan, X Jiang, H Qiao, S Pan, H Jiang, J Kanwar, X Sun

(2010), Vol. 38, pp. 1115-1130, The American journal of Chinese medicine, Toh Tuck Link, Singapore, C1

journal

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-? therapy

C Cheung, X Sun, J Kanwar, J Bai, L Cheng, G Krissansen

(2010), Vol. 10, pp. 1-11, Cancer cell international, London, England, C1

journal

Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases

J Kanwar, R Mohan, R Kanwar, K Roy, R Bawa

(2010), Vol. 5, pp. 1435-1445, Nanomedicine, London, England, C1

journal

Proliferative and protective effects of SurR9-C84A on differentiated neural cells.

S Baratchi, R Kanwar, C Cheung, J Kanwar

(2010), Vol. 227, pp. 120-132, Journal of neuroimmunology, Amsterdam, Netherlands, C1

journal

Recent advances on the possible neuroprotective activities of Epstein-Barr virus oncogene BARF1 protein in chronic inflammatory disorders of central nervous system

A Wynne, R Kanwar, R Khanna, J Kanwar

(2010), Vol. 8, pp. 268-275, Current neuropharmacology, Sharjah, United Arab Emirates, C1

journal

MicroRNA in human cancer and chronic inflammatory diseases

J Kanwar, G Mahidhara, R Kanwar

(2010), Vol. 2, pp. 1113-1126, Frontiers in bioscience (scholar edition), Albertson, N.Y., C1

journal

Recent advances in anti-survivin treatments for cancer

R Kanwar, C Cheung, J Chang, J Kanwar

(2010), Vol. 17, pp. 1509-1515, Current medicinal chemistry, Hilversum, The Netherlands, C1

journal

Applications of nanomedicine in antibacterial medical therapeutics and diagnostics

L Matthews, R Kanwar, S Zhou, V Punj, J Kanwar

(2010), Vol. 3, pp. 1-9, Open tropical medicine journal, Amsterdam, The Netherlands, C1-1

journal
2009

Ribosome inactivating proteins (RIPs) from momordica charantia for anti viral therapy

M Puri, I Kaur, R Kanwar, R Gupta, A Chauhan, J Kanwar

(2009), Vol. 9, pp. 1080-1094, Current molecular medicine, Bussum, Netherlands, C1

journal

Molecular and biotechnological advances in milk proteins in relation to human health

J Kanwar, R Kanwar, X Sun, V Punj, H Matta, S Morley, A Parratt, M Puri, R Sehgal

(2009), Vol. 10, pp. 308-338, Current protein and peptide science, Bussum, Netherlands, C1

journal

Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal

J Kanwar, R Kanwar

(2009), Vol. 10, pp. 1-19, BMC immunology, London, England, C1

journal

Fabrication of ultrafine powder from eri silk through attritor and jet milling

R Rajkhowa, L Wang, J Kanwar, X Wang

(2009), Vol. 191, pp. 155-163, Powder technology, Lausanne, Switzerland, C1

journal

Design and simulation of an interdigital-chaotic advection micromixer for lab-on-a-chip applications

K Khoshmanesh, A Kouzani, S Nahavandi, S Baratchi, J Kanwar

(2009), Vol. 6, pp. 118-124, La houille blanche, Paris, France, C1

journal

Recent advances on the roles of NO in cancer and chronic inflammatory disorders

J Kanwar, R Kanwar, H Burrow, S Baratchi

(2009), Vol. 16, pp. 2373-2394, Current medicinal chemistry, Bussum, Netherlands, C1

journal

Recent advances of metal binding protein lactoferrin as an anti-microbial agent

I Gupta, R Sehgal, R Kanwar, A Sehgal, J Kanwar

(2009), Vol. 5, pp. 226-233, Current bioactive compounds, Bussum, Netherlands, C1

journal

A microfluidic electroosmotic mixer and the effect of potential and frequency on its mixing efficiency

A Kouzani, K Khoshmanesh, S Nahavandi, J Kanwar

(2009), pp. 4618-4622, SMC 2009 : Proceedings of the IEEE Systems, Man and Cybernetics 2009 international conference, San Antonio, Texas, E1

conference

Recent advances in nanoneurology for drug delivery to the brain

J Kanwar, R Kanwar, G Mahidhara

(2009), Vol. 5, pp. 441-447, Current nanoscience, Bussum, Netherlands, C1

journal

Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases

S Baratchi, R Kanwar, K Khoshmanesh, P Vasu, C Ashok, M Hittu, A Parratt, S Krishnakumar, X Sun, S Sahoo, J Kanwar

(2009), Vol. 5, pp. 15-25, Current Nanoscience, Bussum, Netherlands, C1

journal

Design and numerical analysis of magnetic microrotors for micromixing

K Khoshmanesh, A Kouzani, S Nahavandi, J Kanwar, S Baratchi

(2009), pp. 1-5, ASME & IDETC/CIE 2009 : Proceedings of the 2009 International Design Engineering Technical Conferences & Computers and Information in Engineering Conference, San Diego, California, E1

conference

Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6

S Mo, Y Liu, W Duan, M Wei, J Kanwar, S Zhou

(2009), Vol. 10, pp. 730-753, Current drug metabolism, Hilversum, The Netherlands, C1

journal
2008

Immobilized enzyme technology for debittering citrus fruit juices

M Puri, A Kaur, R Singh, J Kanwar

(2008), pp. 91-103, Food enzymes : application of new technologies, Kerala, India, B1

chapter

At a glance: cellular biology for engineers

K Khoshmanesh, A Kouzani, S Nahavandi, S Baratchi, J Kanwar

(2008), Vol. 32, pp. 315-331, Computational biology and chemistry, Oxford, England, C1

journal

Bovine milk fat enriched in conjugated linoleic and vaccenic acids attenuates allergic airway disease in mice

R Kanwar, A MacGibbon, P Black, J Kanwar, A Rowan, M Vale, G Krissansen

(2008), Vol. 38, pp. 208-218, Clinical and experimental allergy, Oxford, England, C1

journal

'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy

J Kanwar, K Palmano, X Sun, R Kanwar, R Gupta, N Haggarty, A Rowan, S Ram, G Krissansen

(2008), Vol. 86, pp. 277-288, Immunology and cell biology, London, England, C1

journal

Design and simulation of an interdigital-chaotic advection micromixer for lab-on-a-chip applications

K Khoshmanesh, A Kouzani, S Nahavandi, S Baratchi, J Kanwar

(2008), pp. 1-9, MicroFlu 2008 : Proceedings of the 1st European Conference on Microfluidics, Universita di Bologna, Italy, E1-1

conference
2006

A pseudosymmetric cell adhesion regulatory domain in the ?7 tail of the integrin ?4?7 that interacts with focal adhesion kinase and src

G Krissansen, J Singh, R Kanwar, Y Chan, E Leung, K Lehnert, J Kanwar, Y Yang

(2006), Vol. 36, pp. 2203-2214, European journal of immunology, Weinheim, Germany, C1-1

journal

Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas

L Luo, H Qiao, F Meng, X Dong, B Zhou, H Jiang, J Kanwar, G Krissansen, X Sun

(2006), Vol. 118, pp. 1823-1830, International journal of cancer, Malden, Mass., C1-1

journal
2005

Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease

J Kanwar

(2005), Vol. 12, pp. 2947-2962, Current medicinal chemistry, Bussum, Netherlands, C1-1

journal

Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors

X Sun, H Qiao, H Jiang, X Zhi, F Liu, J Wang, M Liu, D Dong, J Kanwar, R Xu, G Krissansen

(2005), Vol. 12, pp. 35-45, Cancer gene therapy, London, Eng., C1-1

journal
2004

Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis

J Kanwar, R Kanwar, G Krissansen

(2004), Vol. 127, pp. 1313-1331, Brain : a journal of neurology, Oxford, England, C1-1

journal

Bioassay detects soluble MAdCAM-1 in body fluids

E Leung, K Lehnert, J Kanwar, Y Yang, Y Mon, H McNeil, G Krissansen

(2004), Vol. 82, pp. 400-409, Immunology and cell biology, Basingstoke, England, C1-1

journal
2003

Mucosal vascular addressin cell adhesion molecule-1 is expressed outside the endothelial lineage on fibroblasts and melanoma cells

E Leung, R Kanwar, J Kanwar, G Krissansen

(2003), Vol. 81, pp. 320-327, Immunology and cell biology, Basingstoke, England, C1-1

journal

Requirements for ICAM-1 immunogene therapy of lymphoma.

J Kanwar, R Berg, Y Yang, R Kanwar, L Ching, X Sun, G Krissansen

(2003), Vol. 10, pp. 468-476, Cancer gene therapy, London, England, C1-1

journal

Mouse B7-H3 induces antitumor immunity

X Sun, M Vale, E Leung, J Kanwar, R Gupta, G Krissansen

(2003), Vol. 10, pp. 1728-1734, Gene therapy, London, England, C1-1

journal

Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha

X Sun, J Kanwar, E Leung, M Vale, G Krissansen

(2003), Vol. 10, pp. 2081-2089, Gene Therapy, London, England, C1-1

journal
2001

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci

J Kanwar, R Kanwar, S Pandey, L Ching, G Krissansen

(2001), Vol. 61, pp. 1948-1956, Cancer research, Birmingham, Ala., C1-1

journal

Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice

R Kanwar, J Kanwar, D Wang, D Ormrod, G Krissansen

(2001), Vol. 21, pp. 1991-1997, Arteriosclerosis thrombosis and vascular biology, Philadelphia, Pa., C1-1

journal

Effects of survivin antagonists of growth of established tumors and B7-1 immunogene therapy

J Kanwar, W Shen, R Kanwar, R Berg, G Krissansen

(2001), Vol. 93, pp. 1541-1552, Journal of the National Cancer Institute, Oxford, England, C1-1

journal

Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ

M Rafiee, J Kanwar, R Berg, K Lehnert, K Lisowska, G Krissansen

(2001), Vol. 8, pp. 974-981, Cancer gene therapy, London, Eng., C1-1

journal

Gene transfer of antisense hypoxia inducible factor-1 a enhances the therapeutic efficacy of cancer immunotherapy

X Sun, J Kanwar, E Leung, K Lehnert, D Wang, G Krissansen

(2001), Vol. 8, pp. 638-645, Gene therapy, London, Eng., C1-1

journal

Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression

X Sun, J Kanwar, E Leung, K Lehnert, D Wang, G Krissansen

(2001), Vol. 8, pp. 719-727, Cancer gene therapy, London, Eng., C1-1

journal

Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy

S Kommajosyula, S Reddy, K Nitschke, J Kanwar, M Karanam, G Krissansen

(2001), Vol. 70, pp. 510-517, Journal of leukocyte biology, Bethesda, Md., C1-1

journal
2000

Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression.

J Kanwar, R Kanwar, D Wang, G Krissansen

(2000), Vol. 78, pp. 641-645, Immunology and cell biology, London, England, C1-1

journal

?7 integrins contribute to demyelinating disease of the central nervous system

J Kanwar, J Harrison, D Wang, E Leung, W Mueller, N Wagner, G Krissansen

(2000), Vol. 103, pp. 146-152, Journal of neuroimmunology, Amsterdam, The Netherlands, C1-1

journal
1999

Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity

J Kanwar, R Berg, K Lehnert, G Krissansen

(1999), Vol. 6, pp. 1835-1844, Gene therapy, London, Eng., C1-1

journal
1996

In vitro production of Campylobacter jejuni enterotoxin (CJT) and its characterization through biological assays

R Kaur, A Singh, J Kanwar, M Kalra

(1996), Vol. 31, pp. 427-431, Journal of research : Punjab Agricultural University, Ludhiana, India, C1-1

journal
1995

Calcium and protein kinase C play an important role in Campylobacter jejuni-induced changes in Na+ and Cl- transport in rat ileum in vitro

R Kanwar, N Ganguly, L Kumar, J Rakesh, D Panigrahi, B Walia

(1995), Vol. 1270, pp. 179-192, Biochimica et biophysica acta, Amsterdam, The Netherlands, C1-1

journal
1994

Impairment of Na+,K+-ATPase activity following enterotoxigenic Campylobacter jejuni infection: changes in Na+, Cl-- and 3-O-methyl-D-glucose transport in vitro, in rat ileum

R Kanwar, N Ganguly, J Kanwar, L Kumar, B Walia

(1994), Vol. 124, pp. 381-385, FEMS microbiology letters, Oxford, England, C1-1

journal

Significance of detection of immune-complexed 8 kDa hydatid-specific antigen for immunodiagnosis of hydatidosis

J Kanwar, R Kanwar, A Grewal, V Vinayak

(1994), Vol. 9, pp. 231-236, FEMS immunology & medical microbiology, Oxford, England, C1-1

journal

Purification and partial immunochemical characterization of a low molecular mass, diagnostic Echinococcus granulosus immunogen for sheep hydatidosis

J Kanwar, R Kanwar

(1994), Vol. 9, pp. 101-107, FEMS immunology & medical microbiology, Oxford, England, C1-1

journal

Funded Projects at Deakin

Australian Competitive Grants

Anti-tumour and anti-microbial activities of orally administered Fe-saturated lactoferrin: a potential alternative medicine

Prof Jagat Kanwar, Dr Rupinder Kanwar

DIISR Grant - Australia-India Strategic Research Fund - Department of Innovation, Industry and Regional Development

  • 2011: $28,000
  • 2010: $126,000
  • 2009: $126,000

Locked nucleic acid modified aptamer-siRNA chimeric conjugates for improved chemosensitivity and eradication of cancer stem cells

Prof Jagat Kanwar, Dr Rupinder Kanwar

DIISR Grant - Australia-India Strategic Research Fund - Department of Innovation, Industry and Regional Development

  • 2015: $60,000
  • 2014: $58,030
  • 2013: $90,000
  • 2012: $88,000

Novel ophthalmic formulation to clear transformed myofibroblasts and proliferate keratocytes in corneal haze model

Prof Jagat Kanwar

NHMRC Project Grant

  • 2016: $44,227
  • 2015: $97,006
  • 2014: $104,617
  • 2013: $26,027

Novel biocompatible nickel-free shape memory alloy scaffolds for biomedical applications

Dr Cui'E Wen, Prof Andrejs Atrens, Dr Yuncang Li, Prof Jagat Kanwar

NHMRC Project Grant

  • 2017: $16,875
  • 2016: $22,500

Other Public Sector Funding

NHMRC Equipment Grant 2012

Prof Jagat Kanwar

  • 2013: $16,624

Advanced wound healing protein powder

Dr Rangam Rajkhowa, Prof Jagat Kanwar

  • 2017: $49,541

Industry and Other Funding

Anti-inflammatory and chrondoprotective Effects of Constituent 4

Prof Jagat Kanwar, Dr Xavier Conlan, Prof Andrew Parratt

  • 2008: $160,000

Evaluation of the potential efficacy of Enprocal

Prof Jagat Kanwar, Prof Andrew Parratt

  • 2008: $21,775
  • 2007: $89,225

Novel Nanocapsule Based Cancer Targeted Drug Delivery System

Dr Rupinder Kanwar, Prof Jagat Kanwar, Dr Maysaa Al-Mohammedawi

  • 2012: $20,000

Supervisions

Principal Supervisor
2017

Prasanna Kumar Athyala

Thesis entitled: Oligonucleotide-Conjugates for Targeting EpCAM Positive Tumor Cells

Doctor of Philosophy (Medicine), School of Medicine

2016

Pavan Sunkireddy

Thesis entitled: Development of Anti-Cataract Nanomedicine from Natural Antioxidant Biomolecules

Doctor of Philosophy (Medicine), School of Medicine

2015

Rajneesh Chaudhary

Thesis entitled: Zinc doped ferrite magnetic resonance imaging contrast agent for atherosclerosis

Doctor of Philosophy (Medicine), School of Medicine

Nithya Subramanian

Thesis entitled: MOLECULAR INSIGHTS AND OLIGONUCLEOTIDE BASED TARGETED GENE THERAPY AGAINST CANCER

Doctor of Philosophy (Medicine), School of Medicine

Nihal Ganesh Maremanda

Thesis entitled: Proteomics based biomarker discovery in oral cancer

Doctor of Philosophy (Medicine), School of Medicine

2014

Sishir Kumar Kamalapuram

Thesis entitled: Multimodal therapeutic protein nanocapsules for cancer therapy and imaging

Doctor of Philosophy (Medicine), School of Medicine

Bhasker Sriramoju

Thesis entitled: SurR9-C84A mutant nanocarrier and milk protein therapeutics for neurological disorders

Doctor of Philosophy (Medicine), School of Medicine

Rasika Samarasinghe

Thesis entitled: Anti-inflammatory and chondroprotectivity of dominant-negative survivan and nutraceuticals, lactoferrin and herbs

Doctor of Philosophy (Medicine), School of Medicine

2013

Isha Gupta

Thesis entitled: Anti-microbial activities of novel nanoformulated lactoferrin through oral administration

Doctor of Philosophy (Medicine), School of Medicine

2012

Yogesh Patel

Thesis entitled: Silk as novel nano-carrier for delivering anti-cancer biomolecule lactoferrin

Master of Science (Biology & Chemistry), BioDeakin

VNL Ganesh Mahidhara

Thesis entitled: Anti-cancer nanocarriers for oral delivery of therapeutic proteins

Doctor of Philosophy (Engineering), BioDeakin

2011

Hannah Burrow

Thesis entitled: Bovine Lactoferrin: Potential Antioxidant Effector Molecule in Colon Carcinoma

Doctor of Philosophy (Biol & Chem), BioDeakin

Sara Baratchi

Thesis entitled: Protective and Proliferative Effects of Surviving Mutant on Differentiated Neuroblastoma Cells

Doctor of Philosophy (Life & Env), BioDeakin

Co-supervisor
2017

Sanjukta Chakrabarti

Thesis entitled: Functionality Determination and Characterization of an Angiogenesis-Inhibiting Fusion Protein

Doctor of Philosophy (Life & Env), School of Life and Environmental Sciences

Associate Supervisor
2017

Rajeswari Raguraman

Thesis entitled: Deciphering the role of tumor microenvironment in the invasion and progression of retinoblastoma

Doctor of Philosophy (Medicine), School of Medicine

Sri Balaji Ponraj

Thesis entitled: Nanosecond pulsed Atmospheric Pressure Plasma for Fabrication of Hybrid Nanostructures and Decontamination of Milk

Doctor of Philosophy (Engineering), Institute for Frontier Materials

2016

Narinderbir Singh

Thesis entitled: Targeting Survivin and Molecular Regulation of De-Differentiated Grade IV Astrocytoma (Glioblastoma)

Doctor of Philosophy (Medicine), School of Medicine

2015

Jessica Gibbons

Thesis entitled: Bovine lactoferrin targets apoptotic and EGFR mechanisms in breast cancer

Doctor of Philosophy (Medicine), School of Medicine

Ajay Ashok

Thesis entitled: Novel Protein and Atenolol Co-Encapsulated Nanocapsules to Impede Cardiomyocyte Apoptosis

Doctor of Philosophy (Medicine), School of Medicine

Jayanth Surya Narayanan Shankara Narayanan

Thesis entitled: Molecular regulation of survivin targeted nano-therapy in advanced prostate cancer

Doctor of Philosophy (Medicine), School of Medicine

Neha Singh

Thesis entitled: A natural biodrug targeting melanomas with vaying mutational status

Doctor of Philosophy (Medicine), School of Medicine

2014

Jaisy Samuel

Thesis entitled: Targeting the sodium iodide symporter (NIS) and apoptotic genes in extrathyroidal tumors

Doctor of Philosophy (Medicine), School of Medicine

Masoomeh Tehrani Rokh

Thesis entitled: A 3D CELL-CULTURE AND GRADIENT-GENERATOR MICROFLUIDIC DEVICE

Doctor of Philosophy (Engineering), School of Engineering

Sneha Gurudevan

Thesis entitled: Lactoferrin targets hypoxia inducible factor - 1¿ (HIF-1¿) signaling in liver and colon cancer cells

Doctor of Philosophy (Medicine), BioDeakin

2013

Fawzi Ebrahim

Thesis entitled: Studies on the anticancer potential of high molecular weight bovine lactoferrin in targeting ovarian carcinoma

Master of Science (Biology & Chemistry), BioDeakin

2012

Kathleen McLachlan

Thesis entitled: Development of Combinatorial RNAi Transgenes Targeting Influenza Virus

Master of Science (Biology & Chemistry), School of Life and Environmental Sciences

2010

Khashayar Khoshmanesh

Thesis entitled: Novel Dielectrophoretic Platforms for Manipulation and Separation of Particles

Doctor of Philosophy (Engineering), School of Engineering

Rangam Rajkhowa

Thesis entitled: Fabricating and Characterising Silk Powder for Biomedical and Sorption Applications

Doctor of Philosophy (Engineering), Institute for Frontier Materials